(firstQuint)Velcade for Proliferative Lupus Nephritis.

 This exploratory single center, open-label, single treatment group assignment, safety, and efficacy study will enroll 14 patients with WHO class III/IV/V lupus nephritis.

 Subjects will receive 12 doses of Velcade to induce clinical remission.

.

 Velcade for Proliferative Lupus Nephritis@highlight

The primary objective is to test the safety and efficacy of Velcade to induce remission in WHO class III/IV/V lupus nephritis that are refractory to standard medications.

